|
Market Closed -
Bombay S.E.
06:02:25 2026-10-05 am EDT
|
5-day change | 1st Jan Change | ||
| 2,603.65 INR | -1.09% |
|
-8.73% | +41.41% |
| Sep. 25 | Caplin Point Laboratories Limited Approves Appointment of D Muralidharan as Whole Time Director | CI |
| Aug. 14 | Caplin Point Laboratories Limited, Q1 2027 Earnings Call, Aug 12, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Generic Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 2.08B | - | - | |||
| 1,019B | |||||
| 617B | - | ||||
| 464B | |||||
| 356B | |||||
| 333B |
Select your edition
All financial news and data tailored to specific country editions
